Yuki Tsang

Counsel

Disclaimer

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Yuki Tsang is a counsel in O’Melveny’s Hong Kong office. She focuses her practice on capital markets and mergers and acquisitions. She also advises on regulatory compliance and general commercial matters.

Languages

  • Cantonese
  • Mandarin

Admissions

  • Hong Kong

Education

  • The Chinese University of Hong Kong, P.C.L.L.
  • The Chinese University of Hong Kong, LL.B.

Capital Markets:

  • Sipai Health Technology Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
  • Haitong International Capital Limited and CCB International Capital Limited as joint sponsors, and other underwriters in the IPO and listing of Huafang Group Inc. on the Hong Kong Stock Exchange
  • CICC and China Industrial Securities in the US$64 million top-up share placement and subscription for C&D International
  • ABCI Captial Limited, CICC Hong Kong Securities Limited and other underwriters in the H-share IPO of Lushang Life Services Co., Ltd (2376.HK) on the Hong Kong Stock Exchange
  • CCB International Capital Limited as sole sponsor and other underwriters in the approximately US$85 million IPO and listing of Kangqiao Service Group Limited on the Hong Kong Stock Exchange
  • Brii Biosciences Limited in its US$318 million IPO and listing on the Hong Kong Stock Exchange
  • Dexin China Holdings Company Limited in its US$190 million IPO on the Hong Kong Stock Exchange
  • Enice Holding Company Ltd in its privatization by way of scheme of arrangement in Hong Kong
  • PRC-based property developer in issuance of convertible bonds in the principal amount of HK$150 million as pre-IPO investment by ABCI Investment Management Limited
  • Shenzhen-based ophthalmic hospital group in its proposed listing on the Hong Kong Stock Exchange
  • Hong Kong-based tobacco distributor and manufacturer in its proposed listing on the Hong Kong Stock Exchange
VIEW MORE

Press Releases

In the News